<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084370</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000352114</org_study_id>
    <secondary_id>UAB-0134</secondary_id>
    <nct_id>NCT00084370</nct_id>
  </id_info>
  <brief_title>Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy</brief_title>
  <official_title>Molecular Alterations in Human Ovarian Epithelium Induced by Chemopreventive Agents in Patients at Elevated Inherited Risk of Ovarian Cancer: A Controlled Pilot Study in Ovarian Cancer Chemoprevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. The use of celecoxib before prophylactic oophorectomy&#xD;
      may be an effective way to prevent the development of ovarian epithelial cancer.&#xD;
&#xD;
      PURPOSE: A controlled pilot trial to study the effectiveness of celecoxib in preventing&#xD;
      cancer in patients at high-risk for ovarian epithelial cancer who are undergoing prophylactic&#xD;
      oophorectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare histologic and molecular alterations in tissue biomarkers of patients at high&#xD;
           risk for ovarian cancer treated with celecoxib followed by prophylactic oophorectomy vs&#xD;
           prophylactic oophorectomy only.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare alterations in gene expression pattern in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a pilot study. Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo&#xD;
           prophylactic oophorectomy.&#xD;
&#xD;
        -  Group II: Patients undergo immediate prophylactic oophorectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alteration in the histologic and molecular alterations in tissue biomarkers between patients at high risk for ovarian cancer treated with Celecoxib and treated without Celecoxib both having prophylactic oophorectomy.</measure>
    <time_frame>baseline (day of surgery) and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration in gene expression between group I and group II</measure>
    <time_frame>from baseline (surgery) to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>brca1 Mutation Carrier</condition>
  <condition>brca2 Mutation Carrier</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group II: Patients undergo immediate prophylactic oophorectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oophorectomy</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At high risk for ovarian cancer and meets criteria for 1 of the following:&#xD;
&#xD;
               -  Family history of at least 2 ovarian** or breast cancers* among the patient and&#xD;
                  first- or second-degree relatives in the same lineage&#xD;
&#xD;
                    -  Multiple primary cancers in the same person may fulfill this requirement&#xD;
&#xD;
               -  Ashkenazi Jewish ethnicity AND 1 first-degree or 2 second-degree relatives with&#xD;
                  breast* or ovarian** cancer&#xD;
&#xD;
               -  Ashkenazi Jewish ethnicity AND had prior breast cancer*&#xD;
&#xD;
               -  BRCA1/BRCA2 mutation probability &gt; 20% by BRCAPRO&#xD;
&#xD;
               -  Positive for BRCA1 or BRCA2 mutation&#xD;
&#xD;
               -  First- or second-degree relative with a BRCA1/BRCA2 mutation NOTE: *At least 1&#xD;
                  breast cancer must be premenopausal (diagnosed at age 50 or under if menopausal&#xD;
                  status unknown); ductal carcinoma in situ qualifies as breast cancer&#xD;
&#xD;
        NOTE: **In relatives, only ovarian epithelial cancer, fallopian tube cancer, and primary&#xD;
        papillary serous cancer qualifies as ovarian cancer&#xD;
&#xD;
          -  No prior or concurrent ovarian cancer, including low malignant potential cancers or&#xD;
             primary papillary serous carcinoma of the peritoneum&#xD;
&#xD;
               -  No clinical evidence of ovarian cancer by physical examination, CA 125&#xD;
                  evaluation, and pelvic ultrasound&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  19 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Granulocyte count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  No hemophilia or other bleeding disorder&#xD;
&#xD;
          -  No serious anemia&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Transaminases normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 80 mL/min OR&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No emphysema&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No psychiatric or psychological condition that would preclude giving informed consent&#xD;
&#xD;
          -  No concurrent untreated malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No other medical condition that would preclude blood draws (e.g., chronic infectious&#xD;
             disease)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 3 months since prior adjuvant chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin)&#xD;
             allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 months since prior adjuvant radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy)&#xD;
&#xD;
          -  No prior oophorectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 5 years since prior treatment (excluding hormonal therapy) for metastatic&#xD;
             malignancy&#xD;
&#xD;
          -  No concurrent participation in other ovarian cancer early detection clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E. Partridge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Edward Partridge</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ovarian epithelial cancer</keyword>
  <keyword>BRCA1 mutation carrier</keyword>
  <keyword>BRCA2 mutation carrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

